12:00 AM
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

DegludecPlus insulin degludec/insulin aspart regulatory update

Novo Nordisk said FDA accepted for review an NDA for DegludecPlus to treat Type I and II diabetes. The PDUFA...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >